The ubiquitin-like modifier FAT10 in cancer development

International Journal of Biochemistry and Cell Biology

Volumn 79, Issue , 2016, Pages 451-461

  Aichem, Annette ^a   Groettrup, Marcus ^a,b  

^a UNIVERSITY OF KONSTANZ   (Switzerland)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Carcinogenesis; FAT10; Inflammation; UBD; Ubiquitin proteasome system

Indexed keywords

BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; FAT10; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN MAD2; PROTEIN P53; PROTEIN P62; SMAD2 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; FAT10 GENE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; IMMUNOPRECIPITATION; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; SURVIVAL RATE; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; UBIQUITINS;

EID: 84991571453     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2016.07.001     Document Type: Review

References (105)

1. Abate-Shen, C., Deregulated homeobox gene expression in cancer: cause or consequence?. Nat. Rev. Cancer 2:10 (2002), 777–785.
2. Aichem, A., Pelzer, C., Lukasiak, S., Kalveram, B., Sheppard, P.W., Rani, N., Schmidtke, G., Groettrup, M., USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat. Commun., 1, 2010, 13.
3. Aichem, A., Kalveram, B., Spinnenhirn, V., Kluge, K., Catone, N., Johansen, T., Groettrup, M., The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J. Cell Sci. 125 (2012), 4576–4585.
4. Aichem, A., Catone, N., Groettrup, M., Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1. FEBS J. 281:7 (2014), 1848–1859.
5. Amit, S., Hatzubai, A., Birman, Y., Andersen, J.S., Ben-Shushan, E., Mann, M., Ben-Neriah, Y., Alkalay, I., Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16:9 (2002), 1066–1076.
6. Balkwill, F., Tumour necrosis factor and cancer. Nat. Rev. Cancer 9:5 (2009), 361–371.
7. Bates, E.E., Ravel, O., Dieu, M.C., Ho, S., Guret, C., Bridon, J.M., Ait-Yahia, S., Briere, F., Caux, C., Banchereau, J., Lebecque, S., Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells. Eur. J. Immunol. 27:10 (1997), 2471–2477.
8. Bett, J.S., Kanuga, N., Richet, E., Schmidtke, G., Groettrup, M., Cheetham, M.E., van der Spuy, J., The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway. PLoS One, 7(2), 2012, e30866.
9. Bialas, J., Groettrup, M., Aichem, A., Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation. PLoS One, 3, 2015, e0120329.
10. Bosch-Barrera, J., Menendez, J.A., Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat. Rev. 41:6 (2015), 540–546.
11. Buerger, S., Herrmann, V.L., Mundt, S., Trautwein, N., Groettrup, M., Basler, M., The ubiquitin-like modifier FAT10 is selectively expressed in medullary thymic epithelial cells and modifies T cell selection. J. Immunol. 195:9 (2015), 4106–4116.
12. Canaan, A., Yu, X., Booth, C.J., Lia, J., Lazar, I., Gamfi, S.L., Castille, K., Kohya, N., Nakayama, Y., Liu, Y.C., Eynon, E., Flavell, R., Weissman, S.M., FAT10/diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol. Cell Biol. 26:13 (2006), 5180–5189.
13. Canaan, A., Defuria, J., Perelman, E., Schultz, V., Seay, M., Tuck, D., Flavell, R.A., Snyder, M.P., Obin, M.S., Weissman, S.M., Extended lifespan and reduced adiposity in mice lacking the FAT10 gene. Proc. Natl. Acad. Sci. U. S. A. 111:14 (2014), 5313–5318.
14. Chen, D., Dou, Q.P., The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 11:6 (2010), 459–470.
15. Chen, J., Yang, L., Chen, H., Yuan, T., Liu, M., Chen, P., Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo. Exp. Mol. Pathol. 96:2 (2014), 207–211.
16. Chiu, Y.H., Sun, Q., Chen, Z.J., E1-L2 activates both ubiquitin and FAT10. Mol. Cell 27:6 (2007), 1014–1023.
17. Choi, Y., Kim, J.K., Yoo, J.Y., NFkappaB and STAT3 synergistically activate the expression of FAT10, a gene counteracting the tumor suppressor p53. Mol. Oncol. 8:3 (2014), 642–655.
18. Ciechanover, A., Heller, H., Katz-Etzion, R., Hershko, A., Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc. Natl. Acad. Sci. U. S. A. 78:2 (1981), 761–765.
19. Ciechanover, A., The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17:24 (1998), 7151–7160.
20. Dai, B., Zhang, Y., Zhang, P., Pan, C., Xu, C., Wan, W., Wu, Z., Zhang, J., Zhang, L., Upregulation of p-Smad2 contributes to FAT10-induced oncogenic activities in glioma. Tumour Biol., 2016, 10.1007/s13277-015-4739-6 (in press).
21. de La Coste, A., Romagnolo, B., Billuart, P., Renard, C.A., Buendia, M.A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., Perret, C., Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 95:15 (1998), 8847–8851.
22. Ebstein, F., Lange, N., Urban, S., Seifert, U., Kruger, E., Kloetzel, P.M., Maturation of human dendritic cells is accompanied by functional remodelling of the ubiquitin-proteasome system. Int. J. Biochem. Cell Biol. 41:5 (2009), 1205–1215.
23. Ebstein, F., Lehmann, A., Kloetzel, P.M., The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation. Cell Mol. Life Sci. CMLS 69:14 (2012), 2443–2454.
24. Fan, W., Cai, W., Parimoo, S., Schwarz, D.C., Lennon, G.G., Weissman, S.M., Identification of seven new human MHC class I region genes around the HLA-F locus. Immunogenetics 44:2 (1996), 97–103.
25. Filbin, M.G., Suva, M.L., Glioma genomics and epigenomics: arriving at the start and knowing it for the first time. Annu. Rev. Pathol. 11 (2016), 497–521.
26. Finley, D., Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78 (2009), 477–513.
27. French, S.W., Bardag-Gorce, F., Li, J., French, B.A., Oliva, J., Mallory-Denk body pathogenesis revisited. World J. Hepatol. 2:8 (2010), 295–301.
28. French, S.W., Oliva, J., French, B.A., Li, J., Bardag-Gorce, F., Alcohol, nutrition and liver cancer: role of Toll-like receptor signaling. World J. Gastroenterol. 16:11 (2010), 1344–1348.
29. Gao, Z., Wang, X., Wu, K., Zhao, Y., Hu, G., Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 10:2-3 (2010), 186–193.
30. Gao, Y., Theng, S.S., Zhuo, J., Teo, W.B., Ren, J., Lee, C.G., FAT10, an ubiquitin-like protein, confers malignant properties in non-tumorigenic and tumorigenic cells. Carcinogenesis 35:4 (2014), 923–934.
31. Gao, Y., Theng, S.S., Mah, W.C., Lee, C.G., Silibinin down-regulates FAT10 and modulate TNF-alpha/IFN-gamma-induced chromosomal instability and apoptosis sensitivity. Biol. Open 4:8 (2015), 961–969.
32. Gavin, J.M., Chen, J.J., Liao, H., Rollins, N., Yang, X., Xu, Q., Ma, J., Loke, H.K., Lingaraj, T., Brownell, J.E., Mallender, W.D., Gould, A.E., Amidon, B.S., Dick, L.R., Mechanistic studies on activation of ubiquitin and di-ubiquitin-like protein, FAT10, byubiquitin-like modifier activating enzyme 6, Uba6. J. Biol Chem. 287:19 (2012), 15512–15522.
33. Gong, P., Canaan, A., Wang, B., Leventhal, J., Snyder, A., Nair, V., Cohen, C.D., Kretzler, M., D'Agati, V., Weissman, S., Ross, M.J., The ubiquitin-like protein FAT10 mediates NF-kappaB activation. J. Am. Soc. Nephrol. 21:2 (2010), 316–326.
34. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140:6 (2010), 883–899.
35. Groettrup, M., Pelzer, C., Schmidtke, G., Hofmann, K., Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem. Sci. 33:5 (2008), 230–237.
36. Gu, X., Zhao, F., Zheng, M., Fei, X., Chen, X., Huang, S., Xie, Y., Mao, Y., Cloning and characterization of a gene encoding the human putative ubiquitin conjugating enzyme E2Z (UBE2Z). Mol. Biol. Rep. 34:3 (2007), 183–188.
37. Gudkov, A.V., Gurova, K.V., Komarova, E.A., Inflammation and p53: a tale of two stresses. Genes Cancer 2:4 (2011), 503–516.
38. Haglund, K., Dikic, I., Ubiquitylation and cell signaling. EMBO J. 24:19 (2005), 3353–3359.
39. Han, T., Liu, Z., Li, H., Xie, W., Zhang, R., Zhu, L., Guo, F., Han, Y., Sheng, Y., Xie, X., High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer. Onco Targets Ther. 8 (2015), 1643–1649.
40. Hatzis, P., van der Flier, L.G., van Driel, M.A., Guryev, V., Nielsen, F., Denissov, S., Nijman, J., Koster, J., Santo, E.E., Welboren, W., Versteeg, R., Cuppen, E., van de Wetering, M., Clevers, H., Stunnenberg, H.G., Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol. Cell. Biol. 28:8 (2008), 2732–2744.
41. Heinrich, E.L., Lee, W., Lu, J., Lowy, A.M., Kim, J., Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J. Transl. Med., 10, 2012, 68.
42. Hipp, M.S., Kalveram, B., Raasi, S., Groettrup, M., Schmidtke, G., FAT10, a ubiquitin- independent signal for proteasomal degradation. Mol. Cell. Biol. 25:9 (2005), 3483–3491.
43. Hochstrasser, M., Origin and function of ubiquitin-like proteins. Nature 458:7237 (2009), 422–429.
44. Hoesel, B., Schmid, J.A., The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer, 12, 2013, 86.
45. Hong, Y.K., Foreman, K., Shin, J.W., Hirakawa, S., Curry, C.L., Sage, D.R., Libermann, T., Dezube, B.J., Fingeroth, J.D., Detmar, M., Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat. Genet. 36:7 (2004), 683–685.
46. Ji, F., Jin, X., Jiao, C.H., Xu, Q.W., Wang, Z.W., Chen, Y.L., FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging. World J. Gastroenterol. 15:18 (2009), 2228–2233.
47. Jin, J., Li, X., Gygi, S.P., Harper, J.W., Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447:7148 (2007), 1135–1138.
48. Kalveram, B., Schmidtke, G., Groettrup, M., The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J. Cell Sci. 121:Pt 24 (2008), 4079–4088.
49. Kaminska, B., Kocyk, M., Kijewska, M., TGF beta signaling and its role in glioma pathogenesis. Adv. Exp. Med. Biol. 986 (2013), 171–187.
50. Karin, M., Nuclear factor-kappaB in cancer development and progression. Nature 441:7092 (2006), 431–436.
51. Katoh, M., Katoh, M., Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol. 36:2 (2010), 415–420.
52. Kerscher, O., Felberbaum, R., Hochstrasser, M., Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006), 159–180.
53. Kito, K., Yeh, E.T., Kamitani, T., NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression. J. Biol. Chem. 276:23 (2001), 20603–20609.
54. Lai, T.Y., Su, C.C., Kuo, W.W., Yeh, Y.L., Kuo, W.H., Tsai, F.J., Tsai, C.H., Weng, Y.J., Huang, C.Y., Chen, L.M., Beta-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol. Rep. 26:2 (2011), 415–422.
55. Lara-Gonzalez, P., Westhorpe, F.G., Taylor, S.S., The spindle assembly checkpoint. Curr. Biol. CB 22 (2012), R966–R980.
56. Lee, C.G., Ren, J., Cheong, I.S., Ban, K.H., Ooi, L.L., Yong Ta, n.S., Kan, A., Nuchprayoon, I., Jin, R., Lee, K.H., Choti, M., Lee, L.A., Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 22:17 (2003), 2592–2603.
57. Leng, L., Xu, C., Wei, C., Zhang, J., Liu, B., Ma, J., Li, N., Qin, W., Zhang, W., Zhang, C., Xing Zhai, L., Yang, F., Li, M., Jin, C., Yuan, Y., Xu, P., Qin, J., Xie, H., He, F., Wang, J., A proteomics strategy for the identification of FAT10-modified sites by mass spectrometry. J. Proteome Res. 13:1 (2014), 268–276.
58. Levine, A.J., p53, the cellular gatekeeper for growth and division. Cell 88:3 (1997), 323–331.
59. Li, T., Santockyte, R., Yu, S., Shen, R.F., Tekle, E., Lee, C.G., Yang, D.C., Chock, P.B., FAT10 modifies p53 and upregulates its transcriptional activity. Arch. Biochem. Biophys. 509:2 (2011), 164–169.
60. Liang, Z., Yoon, Y., Votaw, J., Goodman, M.M., Williams, L., Shim, H., Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 65:3 (2005), 967–971.
61. Lim, C.B., Zhang, D., Lee, C.G., FAT10, a gene up-regulated in various cancers, is cell-cycle regulated. Cell Div., 1, 2006, 20.
62. Liu, Y.C., Pan, J., Zhang, C., Fan, W., Collinge, M., Bender, J.R., Weissman, S.M., A MHC-encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly checkpoint protein MAD2. Proc. Natl. Acad. Sci. U. S. A. 96:8 (1999), 4313–4318.
63. Liu, L., Dong, Z., Liang, J., Cao, C., Sun, J., Ding, Y., Wu, D., As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3beta pathway. Oncogene 33:7 (2014), 909–920.
64. Lukasiak, S., Schiller, C., Oehlschlaeger, P., Schmidtke, G., Krause, P., Legler, D.F., Autschbach, F., Schirmacher, P., Breuhahn, K., Groettrup, M., Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27:46 (2008), 6068–6074.
65. Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129:7 (2007), 1261–1274.
66. Merbl, Y., Refour, P., Patel, H., Springer, M., Kirschner, M.W., Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell 152:5 (2013), 1160–1172.
67. Musacchio, A., Salmon, E.D., The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8:5 (2007), 379–393.
68. Nejak-Bowen, K.N., Monga, S.P., Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin. Cancer Biol. 21:1 (2011), 44–58.
69. Nguyen, N.T., Now, H., Kim, W.J., Kim, N., Yoo, J.Y., Ubiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platform. Sci. Rep., 6, 2016, 23377.
70. Oliva, J., Bardag-Gorce, F., French, B.A., Li, J., McPhaul, L., Amidi, F., Dedes, J., Habibi, A., Nguyen, S., French, S.W., Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp. Mol. Pathol. 84:2 (2008), 102–112.
71. Pelzer, C., Kassner, I., Matentzoglu, K., Singh, R.K., Wollscheid, H.P., Scheffner, M., Schmidtke, G., Groettrup, M., UBE1L2, a novel E1 enzyme specific for ubiquitin. J. Biol. Chem. 282:32 (2007), 23010–23014.
72. Peng, X., Shao, J., Shen, Y., Zhou, Y., Cao, Q., Hu, J., He, W., Yu, X., Liu, X., Marian, A.J., Hong, K., FAT10 protects cardiac myocytes against apoptosis. J. Mol. Cell Cardiol. 59 (2013), 1–10.
73. Polakis, P., Wnt signaling and cancer. Genes Dev. 14:15 (2000), 1837–1851.
74. Polakis, P., Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol., 4(5), 2012.
75. Qing, X., French, B.A., Oliva, J., French, S.W., Increased expression of FAT10 in colon benign, premalignant and malignant epithelial neoplasms. Exp. Mol. Pathol. 90:1 (2011), 51–54.
76. Raasi, S., Schmidtke, G., de Giuli, R., Groettrup, M., A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha. Eur. J. Immunol. 29:12 (1999), 4030–4036.
77. Raasi, S., Schmidtke, G., Groettrup, M., The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 276:38 (2001), 35334–35343.
78. Rani, N., Aichem, A., Schmidtke, G., Kreft, S.G., Groettrup, M., FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nat. Commun., 3, 2012, 749.
79. Ren, J., Kan, A., Leong, S.H., Ooi, L.L., Jeang, K.T., Chong, S.S., Kon, O.L., Lee, C.G., FAT10 plays a role in the regulation of chromosomal stability. J. Biol. Chem. 281:16 (2006), 11413–11421.
80. Ren, J., Wang, Y., Gao, Y., Mehta, S.B., Lee, C.G., FAT10 mediates the effect of TNF-alpha in inducing chromosomal instability. J. Cell Sci. 124:Pt 21 (2011), 3665–3675.
81. Reyes-Turcu, F.E., Ventii, K.H., Wilkinson, K.D., Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78 (2009), 363–397.
82. Ross, M.J., Wosnitzer, M.S., Ross, M.D., Granelli, B., Gusella, G.L., Husain, M., Kaufman, L., Vasievich, M., D'Agati, V.D., Wilson, P.D., Klotman, M.E., Klotman, P.E., Role of ubiquitin-like protein FAT10 in epithelial apoptosis in renal disease. J. Am. Soc. Nephrol. 17:4 (2006), 996–1004.
83. Schliehe, C., Bitzer, A., van den Broek, M., Groettrup, M., Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J. Virol. 86:18 (2012), 9782–9793.
84. Schmidtke, G., Kalveram, B., Weber, E., Bochtler, P., Lukasiak, S., Hipp, M.S., Groettrup, M., The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J. Biol. Chem. 281:29 (2006), 20045–20054.
85. Schmidtke, G., Kalveram, B., Groettrup, M., Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett. 583:3 (2009), 591–594.
86. Schmidtke, G., Aichem, A., Groettrup, M., FAT10ylation as a signal for proteasomal degradation. Biochim. Biophys. Acta 1843:1 (2014), 97–102.
87. Singh, R.P., Mallikarjuna, G.U., Sharma, G., Dhanalakshmi, S., Tyagi, A.K., Chan, D.C., Agarwal, C., Agarwal, R., Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res. 10:24 (2004), 8641–8647.
88. Snyder, A., Alsauskas, Z., Gong, P., Rosenstiel, P.E., Klotman, M.E., Klotman, P.E., Ross, M.J., FAT10: a novel mediator of Vpr-induced apoptosis in human immunodeficiency virus-associated nephropathy. J. Virol. 83:22 (2009), 11983–11988.
89. Spinnenhirn, V., Farhan, H., Basler, M., Aichem, A., Canaan, A., Groettrup, M., The ubiquitin-like modifier FAT10 decorates autophagy-targeted Salmonella and contributes to Salmonella resistance in mice. J. Cell Sci. 127:22 (2014), 4883–4893.
90. Sun, G.H., Liu, Y.D., Yu, G., Li, N., Sun, X., Yang, J., Increased FAT10 expression is related to poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 35:6 (2014), 5167–5171.
91. Tarnowski, M., Grymula, K., Reca, R., Jankowski, K., Maksym, R., Tarnowska, J., Przybylski, G., Barr, F.G., Kucia, M., Ratajczak, M.Z., Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol. Cancer Res. MCR 8:1 (2010), 1–14.
92. Theng, S.S., Wang, W., Mah, W.C., Chan, C., Zhuo, J., Gao, Y., Qin, H., Lim, L., Chong, S.S., Song, J., Lee, C.G., Disruption of FAT10-MAD2 binding inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 111:49 (2014), E5282–5291.
93. Tu, Y., Chen, C., Pan, J., Xu, J., Zhou, Z.G., Wang, C.Y., The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int. J. Clin. Exp. Pathol. 5:8 (2012), 726–738.
94. Tyagi, A., Agarwal, C., Dwyer-Nield, L.D., Singh, R.P., Malkinson, A.M., Agarwal, R., Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol. Carcinog. 51:10 (2012), 832–842.
95. Wake, M.S., Watson, C.J., STAT3 the oncogene—still eluding therapy?. FEBS J. 282:14 (2015), 2600–2611.
96. Wang, H., Wang, H.S., Zhou, B.H., Li, C.L., Zhang, F., Wang, X.F., Zhang, G., Bu, X.Z., Cai, S.H., Du, J., Epithelial-mesenchymal transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One, 8(2), 2013, e56664.
97. Weathington, N.M., Mallampalli, R.K., Emerging therapies targeting the ubiquitin proteasome system in cancer. J. Clin. Invest. 124:1 (2014), 6–12.
98. Wolberger, C., Mechanisms for regulating deubiquitinating enzymes. Prot. Sci. 23:4 (2014), 344–353.
99. Xu, P., Duong, D.M., Seyfried, N.T., Cheng, D., Xie, Y., Robert, J., Rush, J., Hochstrasser, M., Finley, D., Peng, J., Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137:1 (2009), 133–145.
100. Yuan, J., Tu, Y., Mao, X., He, S., Wang, L., Fu, G., Zong, J., Zhang, Y., Increased expression of FAT10 is correlated with progression and prognosis of human glioma. Pathol. Oncol. Res. POR 18:4 (2012), 833–839.
101. Yuan, R., Wang, K., Hu, J., Yan, C., Li, M., Yu, X., Liu, X., Lei, J., Guo, W., Wu, L., Hong, K., Shao, J., Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying beta-catenin degradation. Cancer Res. 74:18 (2014), 5287–5300.
102. Zamarron, B.F., Chen, W., Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7:5 (2011), 651–658.
103. Zhang, D.W., Jeang, K.T., Lee, C.G., p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 25:16 (2006), 2318–2327.
104. Zhao, S., Jiang, T., Tang, H., Cui, F., Liu, C., Guo, F., Lu, H., Xue, Y., Jiang, W., Peng, Z., Yan, D., Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy. J. Gastroenterol. Hepatol. 30:4 (2015), 680–688.
105. Zheng, K., Li, H.Y., Su, X.L., Wang, X.Y., Tian, T., Li, F., Ren, G.S., Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. CR, 29, 2010, 31.